Molecular biomarker testing for all patients with metastatic colorectal cancer (CRC) has become increasingly important because identifying targetable alterations can lead to meaningful clinical benefits. At a minimum, testing should include RAS, BRAF mutational status, microsatellite instability status, HER2 expression, NTRK, and RET mutations. For HER2-amplified cancer, the NCCN Guidelines offer multiple treatment options, including trastuzumab in combination with tucatinib or pertuzumab, and trastuzumab-deruxtecan. Combination trastuzumab + tucatinib has recently received approval by the FDA for refractory RAS wild-type, HER2-amplified CRC. The addition of bevacizumab to trifluridine/tipiracil treatment has significantly prolonged median overall survival compared with trifluridine/tipiracil alone, regardless of molecular subtypes. KRAS G12C–targeted therapies are on the horizon, with several agents in ongoing studies. Furthermore, bilevel blockade is important when addressing MAP kinase pathway alterations.
Search Results
Updates in the Treatment of Metastatic Colorectal Cancer
Presented by: Midhun Malla, Katrina S. Pedersen, and Aparna R. Parikh
Thirty Years of Advances in Melanoma
Alan N. Houghton
BPI20-007: Evaluation of Guideline Adherence in Colorectal Cancer Management in a Private Clinic, Lima – Peru
Karina Mayra Aliaga, Fradis Gil-Olivares, Laura Pérez, Gisely Hijar, Edward López, Cindy Alcarraz, Mariana Serrano, Claudio Flores, Alonso Díaz, Jose Gutierrez, and Alfredo Aguilar
RAS and BRAF mutational status to patients with metastatic CRC and percentage of patients who received recommended therapy according to the RAS and/or BRAF mutational status. Methods: A descriptive analysis was performed. Indicators were compared
CLO23-047: Ivosidenib as a Novel Treatment for Patients With Isocitrate Dehydrogenase-1 Positive Advanced Colon Cancer
Krishna Desai, Kristal Pereira, Akhil Jain, Sabah Iqbal, and Rajesh Thirumaran
, fluorouracil, & oxaliplatin) was started, but a new metastatic lesion in the liver was found. In the interim, NGS was positive for IDH-1 & BRAF mutation. Since he was progressing, target therapy with Ivosidenib was added for IDH-1, as per NGS. At 2 year follow
NCCN News
.2011 (Rectal). Based upon recent presentations, the previous footnote related to BRAF mutations was removed and the following footnotes were added to the metastatic section of the NCCN Guidelines for Colon and Rectal Cancers: Footnote in the first
NCCN Guidelines Updates: Management of Metastatic Colorectal Cancer
Wells A. Messersmith
the NTRK inhibitor larotrectinib, and some additional language regarding Lynch syndrome and testing, both in terms of expression of the markers and the fact that a BRAF mutation doesn’t rule out Lynch syndrome,” he said at the NCCN 2019 Annual
Oncology Research Program
Trametinib (MEKi) in Patients With BRAF Mutation or BRAF Gene Fusion Defect in Thyroid Carcinoma Protocol Chair: Manisha Shah, MD Institutional Principal Investigators: Manisha Shah, MD; Naifa L. Busaidy, MD; Lori Wirth, MD; Jonas DeSouza, MD; and
Oncology Research Program
safety of the orally administered MEK inhibitor trametinib in subjects with melanoma harboring mutations in BRAF at locations other than codon 600 (atypical BRAF mutations; BRAF non-V600MUT) or BRAF fusions. More than 5% of melanomas harbor these
Oncology Research Program
and safety of the orally administered MEK inhibitor trametinib (GSK1120212) in subjects with melanoma harboring mutations in BRAF at locations other than codon 600 (atypical BRAF mutations; BRAF non-V600 MUT ) or BRAF fusions. More than 5% of
Oncology Research Program
Protocol Chair: Manisha Shah, MD Institutional Principal Investigators: Manisha Shah, MD, and Filip Janku, MD, PhD Condition: Adult malignant tumors with BRAF mutation Institutions: The Ohio State University Comprehensive Cancer Center - James
